Takeda will also present 14 scientific updates regarding its gene therapy pipeline for both hemophilia A and B. The goal of gene therapy is to enable a hemophilia patient’s body to naturally produce a sufficient amount of the missing factor VIII or IX to alleviate bleeding episodes.3Therefore,...
In addition to PROPEL, Takeda are presenting 47 other data updates across the hematology portfolio. Most notably, 14 presentations will unveil some of the foundational work being carried out within the Takeda Hematology gene therapy pipeline, looking at ways to help hemophilia patients naturally produc...
“Takeda is an ideal partner to maximize the potential of our ImmTOR platform in gene therapy. Their extensive capabilities as a global biopharmaceutical leader and expertise in rare diseases gives us a high degree of confidence...
In addition to PROPEL, Takeda are presenting 47 other data updates across the hematology portfolio. Most notably, 14 presentations will unveil some of the foundational work being carried out within the Takeda Hematology...
the Cell Therapy Technology Product Engine, Clinical Science, Clinical Operations, Portfolio Strategy, the Data Sciences Institute, and Program Management as well as external partners and thought leaders to infuse translational excellence to advance the pipeline. This leader will also partner on broader ...
We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diver...
“This agreement also supports our strategy of using partnering selectively to continue to invest in our Targeted RNAi Molecule (TRiMTM) platform and the growing pipeline of RNAi therapeutics targeting diverse tissue types, while focusing our commercial organization on opportunities in two key areas of...
“FDA approval of the Oncomine Dx Target Test as a companion diagnostic for Exkivity will allow clinicians to identify key biomarkers in patients who could benefit from this targeted therapy. “Working closely with Takeda to scale the clinical adoption of the test as a companion diagnostic for Ex...
In addition to PROPEL, Takeda are presenting 47 other data updates across the hematology portfolio. Most notably, 14 presentations will unveil some of the foundational work being carried out within the Takeda Hematology gene therapy pipeline, looking at ways to help hemophilia patients naturally produc...
Advancing the Promise of Gene Therapy in Hemophilia Takeda will also present 14 scientific updates regarding its gene therapy pipeline for both hemophilia A and B. The goal of gene therapy is to enable a hemophilia patient’s body to naturally produce a sufficient amount of the missing factor VI...